Clinical Trial Search

Primary: Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration. — 3.6; 5.3; 7.9 mmol/L

Primary: Percentage of Subjects With Normalized Serum Sodium Concentration on the Day After Final IMP Administration — 43.8; 80; 80; 85.7 percentage of participants

Primary: Change in Sodium Levels From Start of Treatment With Tolvaptan Until Hospital Discharge — 10.3 mmol/L

Primary: Number of Patients Managed According to the SEOM Algorithm (as a Result Adherence to the Algorithm Will be the % of These Patients Among the Total Number of Patients)…

Primary: Participants Whose Serum Sodium Concentration Corrected to at Least 135 mEq/L on Day 14 — 16; 1 participants

Primary: Participants With Adverse Events (AEs) — 105; 76; 73; 19 participants

Primary: Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus — 48 months

Primary: Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients — 96.3; 77.1; 66.7; 100 percentage of patients

Primary: Median Urine Output at 24 Hours Post Randomization — 2910; 3150 mL

Primary: Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment — 87.19…

Primary: Incidence of Hyponatremia (Defined as Serum Sodium Less Than 130 mmol/L) — 1; 2; 8 participants — p=<0.05

Primary: 24hr Urinary Sodium — 16.8; 280; 14.7; 245 milliequivalents

Primary: Bronchial Secretion Volume Over Preceding 24 Hour Period — 220; 310; 200; 70 mL/24 hr

Primary: Hospital Acquired Hyponatremia — 10; 11; 1 participants

Primary: Total Natriuresis After 24 Hours — 409; 345 mmol

Primary: Hyponatremia — 6; 1 Participants — p=0.71